Journal of Hepatology · 2008 · 40 citations · 24 references
MedicineImmunologyInfectious DiseasesImmunizationVaccinologyVirologyHumoral ImmunityOccupational ImmunizationVaccinationVaccine-preventable DiseasesViral HepatitisViral VaccinesBooster Vaccination TrialsHepatitis B Surface Antigen MonitoringHepatitis B Virus ProphylaxisHepatitis Virus VaccinationRepeated Booster VaccinationSerologic Response To Booster Vaccination
BackgroundIndividuals who reach the antibody threshold level of 10 IU/l against the surface protein of the hepatitis B virus (HBV) after completion of a series of hepatitis B vaccination are considered to be long-term protected against a clinically manifest HBV infection.Case reportHere we describe an acute hepatitis B infection in a patient who received five hepatitis B vaccinations. Although his initial response to vaccination was moderate, he finally reached an excellent hepatitis B surface antibody level (anti-HBs) titres of more than 1000 IU/l in response to a booster vaccination with a recombinant DNA vaccine. Nevertheless, he developed full-blown acute hepatitis due to an HBV infection 14 years after this booster vaccination. A DNA analysis of the surface protein encoding region followed by phylogenetic analysis showed that our patient was infected with a normal HBV strain that is circulating among men who have sex with men. To our knowledge, this is the first report of a genuine hepatitis B vaccination failure in someone who acquired a high anti-HBs level in response to a recombinant DNA hepatitis B vaccine.ConclusionHealthcare workers whose response to the initial hepatitis B vaccination is moderate might be vulnerable to hepatitis B virus infection. Individuals who reach the antibody threshold level of 10 IU/l against the surface protein of the hepatitis B virus (HBV) after completion of a series of hepatitis B vaccination are considered to be long-term protected against a clinically manifest HBV infection. Here we describe an acute hepatitis B infection in a patient who received five hepatitis B vaccinations. Although his initial response to vaccination was moderate, he finally reached an excellent hepatitis B surface antibody level (anti-HBs) titres of more than 1000 IU/l in response to a booster vaccination with a recombinant DNA vaccine. Nevertheless, he developed full-blown acute hepatitis due to an HBV infection 14 years after this booster vaccination. A DNA analysis of the surface protein encoding region followed by phylogenetic analysis showed that our patient was infected with a normal HBV strain that is circulating among men who have sex with men. To our knowledge, this is the first report of a genuine hepatitis B vaccination failure in someone who acquired a high anti-HBs level in response to a recombinant DNA hepatitis B vaccine. Healthcare workers whose response to the initial hepatitis B vaccination is moderate might be vulnerable to hepatitis B virus infection.
24
Eric E. Mast, Cindy M. Weinbaum, Anthony E. Fiore et al. · PubMed · 2006 · 1.1K citations
W. Szmuness, Cladd E. Stevens, Edward J. Harley et al. · New England Journal of Medicine · 1980 · 1.1K citations
Vaccine-induced escape mutant of hepatitis B virus
William F. Carman, Peter Karayiannis, Jennifer A. Waters et al. · The Lancet · 1990 · 1.1K citations